Please provide your email address to receive an email when new articles are posted on . “The cell-free DNA is the first blood-based test with performance that is comparable to current guideline ...
Medical students and new physicians at Philadelphia-based Temple Health are trying to close the gap in CRC screening rates with a free, at-home test kit program, ABC 6 reported Oct. 8. The Access ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “More than three out of four Americans who die from ...
New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...
A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...
cf-bDNA testing can reduce CRC incidence and mortality but is less effective and more costly than colonoscopy and FIT. The test may increase screening participation among those who avoid traditional ...
The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...
Results of multi-institutional clinical study published in peer reviewed journal ‘Cancers’ confirms efficacy of Oxford BioDynamics’ EpiSwitch ® blood-based Colorectal No-Stool Test (NST) High accuracy ...
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
Mailing mt-sDNA tests to Medicare Advantage enrollees improved CRC screening adherence, with a 49.4% overall adherence rate. Digital outreach, especially combining email and text, significantly ...
Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based colorectal cancer (CRC) screening test in the US. Exact ...
The FDA granted Check-Cap’s C-Scan an investigational device exemption March 15 that will allow the test to launch a clinical study in the U.S. The C-Scan test is a capsule-based screening technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results